Adaptimmune Therapeutics Plc Strategic Asset Allocation Index
Adaptimmune Therapeutics Plc strategic asset allocation index. Adaptimmune Therapeutics Plc (ADAP) has a Strategic Asset Allocation Index of 83.8% as of September 2023. Strategic assets (PP&E of $73.87 Million plus long-term investments of $-) total $73.87 Million, measured against net assets of $88.13 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Adaptimmune Therapeutics Plc (ADAP) balance sheet quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Adaptimmune Therapeutics Plc (2013–2022)
Strategic asset allocation index of Adaptimmune Therapeutics Plc from 2013 to 2022. This chart shows how Adaptimmune Therapeutics Plc's Strategic Asset Allocation Index has evolved across 10 annual periods from 2013 to 2022. As of September 2023, the index stands at 83.8%, representing strategic assets of $73.87 Million against net assets of $88.13 Million USD. Check how tangible is Adaptimmune Therapeutics Plc's equity to evaluate the tangible quality of the company's equity base.
Adaptimmune Therapeutics Plc Strategic Asset Allocation Index by Year (2013–2022)
Adaptimmune Therapeutics Plc strategic asset allocation index by year from 2013 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Adaptimmune Therapeutics Plc from 2013 to 2022, covering 10 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Adaptimmune Therapeutics Plc (ADAP) market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 87.4% | $71.53 Million | $71.53 Million | $- | $81.88 Million | ▲ +72.6 pp |
| 2021 | 14.8% | $30.49 Million | $30.49 Million | $- | $205.96 Million | ▲ +6.7 pp |
| 2020 | 8.1% | $27.78 Million | $27.78 Million | $- | $341.23 Million | ▼ -17.0 pp |
| 2019 | 25.1% | $31.07 Million | $31.07 Million | $- | $123.64 Million | ▲ +10.5 pp |
| 2018 | 14.6% | $36.12 Million | $36.12 Million | $- | $246.88 Million | ▼ -5.4 pp |
| 2017 | 20.0% | $40.68 Million | $40.68 Million | $- | $202.98 Million | ▲ +3.2 pp |
| 2016 | 16.8% | $27.90 Million | $27.90 Million | $- | $166.14 Million | ▲ +11.7 pp |
| 2015 | 5.1% | $13.22 Million | $13.22 Million | $- | $259.61 Million | ▲ +3.0 pp |
| 2014 | 2.1% | $5.39 Million | $5.39 Million | $- | $259.61 Million | ▼ -57.5 pp |
| 2013 | 59.6% | $1.44 Million | $1.44 Million | $- | $2.41 Million | — |